Protein / target

Lanosterol 14-alpha demethylase

ERG11P10613Candida albicans (strain SC5314 / ATCC MYA-2876)Swiss-Prot
UniProt: P10613NCBI Gene: 3641571
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Sterol 14-demethylase activity

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Sterol 14alpha-demethylase that plays a critical role in the third module of ergosterol biosynthesis pathway, being ergosterol the major sterol component in fungal membranes that participates in a variety of functions (PubMed:10393548, PubMed:28258218, PubMed:8647850, PubMed:9559662). The third module or late pathway involves the ergosterol synthesis itself through consecutive reactions that mainly occur in the endoplasmic reticulum (ER) membrane (By similarity). In filamentous fungi, during the initial step of this module, lanosterol (lanosta-8,24-dien-3beta-ol) can be metabolized to eburicol (By similarity). Sterol 14alpha-demethylase catalyzes the three-step oxidative removal of the 14alpha-methyl group (C-32) of both these sterols in the form of formate, and converts eburicol and lanosterol to 14-demethyleburicol (4,4,24-trimethylergosta-8,14,24(28)-trienol) and 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol, respectively, which are further metabolized by other enzymes in the pathway to ergosterol (PubMed:10393548, PubMed:28258218, PubMed:8647850, PubMed:9559662). Can also use substrates not intrinsic to fungi, such as 24,25-dihydrolanosterol (DHL), producing 4,4-dimethyl-8,14-cholestadien-3-beta-ol, but at lower rates than the endogenous substrates (By similarity)

Subcellular location

Endoplasmic reticulum membrane
Domains and Gene Ontology detail (14)

Gene Ontology

  • Ccortical endoplasmic reticulum
  • Cendoplasmic reticulum membrane
  • Cmembrane
  • Cperinuclear endoplasmic reticulum
  • Cplasma membrane
  • Fheme binding
  • Firon ion binding
  • Foxidoreductase activity
  • Fsterol 14-demethylase activity
  • Pcell growth mode switching, budding to filamentous
  • Pcellular response to xenobiotic stimulus
  • Pendosome organization

528 aa · 61 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Metabolic enzyme activityGO
View supporting evidence

Metabolic enzyme activity

  • ·oxidoreductase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Voriconazole
Narrow target profileInhibitor

Cytochrome P450 51 inhibitor

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (< 12 Years Old)NA

COMPLETED · via Voriconazole · NCT01344512

A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell MalignanciesPHASE1

COMPLETED · via Voriconazole · NCT04551963

An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To <12 Years Who Are At High Risk For Systemic Fungal InfectionPHASE2

COMPLETED · via Voriconazole · NCT00739934

Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin B Sequential Itraconazole TherapyNA

UNKNOWN · via Voriconazole · NCT03827278

A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.PHASE3

TERMINATED · via Voriconazole · NCT00836875

An Open Intravenous Multiple Dose, Multi-Center Study to Investigate the Pharmacokinetics, Safety and Toleration of Voriconazole in Children Aged 2-12 Years Who Require Treatment for the Prevention of Systemic Fungal InfectionPHASE1

COMPLETED · via Voriconazole · NCT00005912

Show remaining trials (24)
Impact of Genetic Polymorphism on Drug Interactions Involving CYP2C19: Risk of Phenoconversion in Healthy CYP2C19 Fast, Normal and Intermediate Metabolizers StatusPHASE1

UNKNOWN · via Voriconazole · NCT05264142

A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric SubjectsPHASE3

TERMINATED · via Voriconazole · NCT01092832

Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene TreatmentPHASE4

TERMINATED · via Voriconazole · NCT00620074

Open, Randomized Comparative Trial of Two Different Schedules of Liposomal Amphotericin B Versus Oral Voriconazole for the Prevention of Invasive Fungal InfectionsPHASE2

COMPLETED · via Voriconazole · NCT00418951

Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence TherapyPHASE4

COMPLETED · via Voriconazole · NCT01539330

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal InfectionsPHASE3

COMPLETED · via Voriconazole · NCT00001757

A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 YearsPHASE3

WITHDRAWN · via Voriconazole · NCT01188759

A Randomized, Open-label, Two-Treatment, Two-Period, Two-Sequence, Cross-over Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend) in Healthy Male VolunteersPHASE1

COMPLETED · via Voriconazole · NCT01657201

A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)PHASE3

COMPLETED · via Voriconazole · NCT01782131

PIVOTAL: Pharmacological Individualisation of VOriconazole Therapy for AntifungaL TreatmentPHASE2

SUSPENDED · via Voriconazole · NCT01887457

A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep MycosisPHASE3

COMPLETED · via Voriconazole · NCT03471988

Effect of Cytochrome P450 2B6 Genetic Polymorphism and Voriconazole on CYP2B6 Activity in Healthy VolunteersNA

COMPLETED · via Voriconazole · NCT01104376

A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive AspergillosisPHASE3

COMPLETED · via Voriconazole · NCT00531479

Clinical Study on the Drug Interaction Between Buagafuran Capsules and Voriconazole Tablets in Chinese Adult Healthy ParticipantsPHASE1

NOT_YET_RECRUITING · via Voriconazole · NCT07457203

A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal InfectionPHASE3

COMPLETED · via Voriconazole · NCT02180165

A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida InfectionsPHASE3

COMPLETED · via Voriconazole · NCT00413218

Pharmacologic Optimization of Voriconazole - a Prospective Clustered Group-randomized Cross-over Trial of Therapeutic Drug MonitoringPHASE3

COMPLETED · via Voriconazole · NCT00893555

The Effect and Safety of Three Initial Introduction Treatments on HIV-infected Patients With Cryptococcal Meningitis: A Multi-center, Random and Prospective StudyEARLY_PHASE1

UNKNOWN · via Voriconazole · NCT04072640

A Clinical Study Evaluating the Effects of Dexamethasone on the Activities of CYP2C9, CYP2C19, and CYP3A4 Substrates in Healthy Male SubjectsPHASE1

NOT_YET_RECRUITING · via Voriconazole · NCT07426042

To Assess Safety, PK of Inhaled Voriconazole (ZP-059) Single Doses in Healthy Subjects (Part 1), ZP-059 Multiple Doses in Stable Asthma (Part 2) and in a Crossover Trial of ZP-059 and Oral Voriconazole Single Doses in Stable Asthma (Part 3)PHASE1

COMPLETED · via Voriconazole · NCT04229303

Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient PopulationsPHASE3

COMPLETED · via Voriconazole · NCT00689338

A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary AspergillosisPHASE3

COMPLETED · via Voriconazole · NCT04824417

A Clinical Trail to Investigate the Influence of SLCO2B1 Polymorphism on the Pharmacokinetic Characteristics of Voriconazole in CYP2C19 Poor MetabolizersPHASE1

COMPLETED · via Voriconazole · NCT02906176

Study to Assess the Pharmacokinetic Drug - Drug Interactions Between Atazanavir Plus Ritonavir Coadministered With Voriconazole in Healthy SubjectsPHASE1

COMPLETED · via Voriconazole · NCT00833482

ClinicalTrials.gov via the drug-target graph.

What's happening now

17

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2025-09-16

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  2. Label change2022-11-29

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  3. Label change2022-11-29

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  4. Label change2022-06-13

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  5. Label change2022-06-13

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  6. Label change2022-06-13

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  7. Label change2022-06-13

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  8. Label change2022-06-13

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  9. New publication2020-12-14
    Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

    The Lancet. Infectious diseases · 2021 · 672 citations · Europe PMC · via Voriconazole

  10. Label change2019-06-28

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  11. Label change2019-06-28

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

  12. Label change2019-06-28

    Label change: VORICONAZOLE (ANDA203503)

    fda · regulatory · fda · via Voriconazole

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.